Rexahn Pharmaceuticals Company Profile (NYSEMKT:RNN)

About Rexahn Pharmaceuticals (NYSEMKT:RNN)

Rexahn Pharmaceuticals logoRexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:RNN
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $100.42 million
  • Outstanding Shares: 25,422,000
Average Prices:
  • 50 Day Moving Avg: $1.93
  • 200 Day Moving Avg: $0.67
  • 52 Week Range: $0.38 - $7.10
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.20
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.05 per share
  • Price / Book: 79.00
Profitability:
  • EBIDTA: ($15,470,000.00)
Misc:
  • Average Volume: 5.87 million shs.
  • Beta: 0.14
  • Short Ratio: 2.4
 

Frequently Asked Questions for Rexahn Pharmaceuticals (NYSEMKT:RNN)

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "RNN."

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) issued its quarterly earnings data on Monday, August, 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.01. View Rexahn Pharmaceuticals' Earnings History.

Where is Rexahn Pharmaceuticals' stock going? Where will Rexahn Pharmaceuticals' stock price be in 2017?

3 brokerages have issued twelve-month price objectives for Rexahn Pharmaceuticals' shares. Their forecasts range from $2.00 to $19.50. On average, they anticipate Rexahn Pharmaceuticals' share price to reach $8.17 in the next twelve months. View Analyst Ratings for Rexahn Pharmaceuticals.

Who are some of Rexahn Pharmaceuticals' key competitors?

Who owns Rexahn Pharmaceuticals stock?

Rexahn Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (22.65%), Vanguard Group Inc. (20.54%), Geode Capital Management LLC (5.08%) and Hudson Valley Investment Advisors Inc. ADV (0.08%). View Institutional Ownership Trends for Rexahn Pharmaceuticals.

Who bought Rexahn Pharmaceuticals stock? Who is buying Rexahn Pharmaceuticals stock?

Rexahn Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC and Geode Capital Management LLC. View Insider Buying and Selling for Rexahn Pharmaceuticals.

How do I buy Rexahn Pharmaceuticals stock?

Shares of Rexahn Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Rexahn Pharmaceuticals stock cost?

One share of Rexahn Pharmaceuticals stock can currently be purchased for approximately $3.95.

Analyst Ratings

Consensus Ratings for Rexahn Pharmaceuticals (NYSEMKT:RNN) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.17

Analysts' Ratings History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Show:
DateFirmActionRatingPrice TargetDetails
5/22/2017HC WainwrightReiterated RatingBuy$19.50View Rating Details
4/6/2017Rodman & RenshawReiterated RatingBuy -> Buy$2.00View Rating Details
2/27/2017FBR & CoReiterated RatingOutperform$3.00View Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$1.75View Rating Details
8/14/2015MLV & Co.Reiterated RatingBuy$1.25View Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Earnings by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Earnings History by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q216($0.02)($0.01)ViewN/AView Earnings Details
5/9/2016Q116($0.02)($0.02)ViewN/AView Earnings Details
11/3/2015Q315($0.03)($0.02)ViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.02)ViewN/AView Earnings Details
4/6/2015($0.03)($0.01)ViewN/AView Earnings Details
3/17/2015($0.02)($0.02)ViewN/AView Earnings Details
11/14/2014($0.03)($0.02)ViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.02)ViewN/AView Earnings Details
3/25/2014($0.06)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Current Year EPS Consensus Estimate: $-0.20 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS

Dividends

Dividend History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Insider Trades by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Institutional Ownership by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Insider Trades by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/10/2017Chang Ho AhnDirectorSell250,000$0.70$175,000.00View SEC Filing  
1/12/2015Chang Ho AhnDirectorSell314,656$0.91$286,336.96View SEC Filing  
1/12/2015Tae Heum JeongCFOSell317,272$0.91$288,717.52View SEC Filing  
6/12/2014Chang Ho AhnDirectorSell136,193$0.99$134,831.07View SEC Filing  
9/9/2013Tae Heum JeongCFOSell71,139$0.46$32,723.94View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Latest Headlines for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Source:
DateHeadline
americanbankingnews.com logoHC Wainwright Reaffirms Buy Rating for Rexahn Pharmaceuticals, Inc. (RNN)
www.americanbankingnews.com - May 22 at 10:54 AM
globenewswire.com logoRexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 ... - GlobeNewswire (press release)
globenewswire.com - May 8 at 6:56 PM
finance.yahoo.com logoRexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
finance.yahoo.com - May 8 at 11:44 AM
streetinsider.com logoRexahn Pharma (RNN) to Trade on Split-Adjusted Basis at Opening; Effects 1-for-10 Reverse Stock Split
www.streetinsider.com - May 6 at 12:50 AM
streetinsider.com logoRexahn Pharma (RNN) to Trade on Split-Adjusted Basis at Opening ... - StreetInsider.com
www.streetinsider.com - May 5 at 7:53 PM
finance.yahoo.com logoRexahn Effects 1-for-10 Reverse Stock Split
finance.yahoo.com - May 5 at 7:49 PM
finance.yahoo.com logoRexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 4 at 7:47 PM
americanbankingnews.com logoRexahn Pharmaceuticals (RNN) Given News Impact Score of 0.10
www.americanbankingnews.com - May 3 at 1:03 AM
americanbankingnews.com logoRexahn Pharmaceuticals (RNN) Earns News Sentiment Score of 0.20
www.americanbankingnews.com - April 28 at 6:54 PM
americanbankingnews.com logoRexahn Pharmaceuticals (RNN) Given News Sentiment Score of 0.31
www.americanbankingnews.com - April 25 at 7:42 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Very Unlikely to Affect Rexahn Pharmaceuticals (RNN) Share Price
www.americanbankingnews.com - April 22 at 3:33 PM
americanbankingnews.com logoSomewhat Negative Media Coverage Unlikely to Affect Rexahn Pharmaceuticals (RNN) Stock Price
www.americanbankingnews.com - April 18 at 7:59 PM
seekingalpha.com logoCould Rexahn Pharmaceuticals Have Something?
seekingalpha.com - April 17 at 6:37 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Very Unlikely to Effect Rexahn Pharmaceuticals (RNN) Stock Price
www.americanbankingnews.com - April 14 at 8:47 PM
finance.yahoo.com logoRexahn Announces 1-for-10 Reverse Stock Split
finance.yahoo.com - April 13 at 9:51 AM
americanbankingnews.com logoChang Ho Ahn Sells 250,000 Shares of Rexahn Pharmaceuticals, Inc. (RNN) Stock
www.americanbankingnews.com - April 12 at 8:09 PM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Given a $2.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 7 at 10:44 PM
streetinsider.com logoRodman & Renshaw Assumes Rexahn Pharmaceuticals Inc. (RNN) at Buy - StreetInsider.com
www.streetinsider.com - April 7 at 7:56 PM
streetinsider.com logoRodman & Renshaw Assumes Rexahn Pharmaceuticals Inc. (RNN) at Buy
www.streetinsider.com - April 7 at 12:20 PM
americanbankingnews.com logoRexahn Pharmaceuticals, Inc. (RNN) Coverage Initiated at Rodman & Renshaw
www.americanbankingnews.com - April 6 at 11:55 AM
zacks.com logoRexahn Pharmaceuticals (RNN) Jumps: Stock Moves Up 5.4%
www.zacks.com - March 16 at 8:10 AM
streetinsider.com logoRexahn Pharma (RNN): First Patient Dosed in Phase IIa, Expect Interim Efficacy Readout in 2017 - FBR - StreetInsider.com
www.streetinsider.com - March 1 at 7:51 PM
finance.yahoo.com logoRexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update
finance.yahoo.com - February 27 at 9:30 AM
finance.yahoo.com logoRexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer
finance.yahoo.com - February 23 at 7:43 PM
finance.yahoo.com logoRexahn Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
finance.yahoo.com - February 6 at 7:42 PM
streetinsider.com logoRexahn Pharma (RNN): Niche in Pancreatic Cancer Looks ... - StreetInsider.com
www.streetinsider.com - January 24 at 8:06 AM

Social

This page was last updated on 5/26/2017 by MarketBeat.com Staff